Reimbursed Care Access in Saint Vincent and the Grenadines

Currently classified as a strictly controlled substance under the national Drugs (Prevention of Misuse) legislative framework with no authorised medical use or reimbursement outside approved clinical research. National legislation in Saint Vincent and the Grenadines lists psilocybin/psilocin among controlled psychotropic substances; there is no published national medical program or public insurance reimbursement for psilocybin therapy. Enforcement intensity may vary locally, but legal status remains prohibition except for authorised research. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use or reimbursement outside of approved clinical research. MDMA (3,4‑methylenedioxymethamphetamine) is controlled under the country’s implementation of international psychotropic drug control conventions and is not part of any reimbursed medical program in Saint Vincent and the Grenadines. # #.

Esketamine (marketed internationally as Spravato) is not documented as authorised or listed on a national reimbursed medicines programme in Saint Vincent and the Grenadines; there is no public evidence of local reimbursement pathways or a certified distribution program for esketamine in the territory. Ketamine itself is a WHO‑listed essential injectable anaesthetic commonly used worldwide, which supports the likelihood that racemic ketamine is available for anaesthesia in medical facilities, but esketamine—an authorised, controlled nasal product in some high‑income jurisdictions—is not known to be registered or reimbursed in Saint Vincent and the Grenadines. For ketamine’s recognised role as an essential anaesthetic: WHO Model List of Essential Medicines (ketamine listed). For lack of local esketamine programme, no national formulary or ministry listing has been identified. # #.

Ketamine is recognised internationally and on the WHO Model List of Essential Medicines as an injectable anaesthetic and is therefore the agent most likely available and used within Saint Vincent and the Grenadines’ health services for anaesthesia and emergency care; such use is part of routine, non‑psychedelic medical practice and would be covered as part of standard hospital care where available. #.

However, the use of ketamine as a psychiatric treatment (e.g., repeated subanaesthetic infusions for treatment‑resistant depression) is an off‑label indication in most jurisdictions and is not supported by a formal, publicly reimbursed national programme in Saint Vincent and the Grenadines. There is no published evidence of public insurance reimbursement or certified outpatient ketamine‑for‑depression clinics operating under a reimbursed pathway in the country; any such use would be private, off‑label, and at patient expense, or limited to authorised clinical research. National drug control instruments regulate ketamine’s supply and professional medical use and do not create a reimbursed psychedelic‑therapy pathway. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT (N,N‑dimethyltryptamine) appears in schedules of internationally controlled psychotropic substances and is treated as prohibited under domestic implementing legislation in Saint Vincent and the Grenadines. No reimbursed medical programme exists locally. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT is not part of any recognised reimbursed medical therapy in Saint Vincent and the Grenadines and would be prohibited except within authorised research settings. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no official, reimbursed medical pathway for ibogaine‑assisted treatment of substance use disorders in Saint Vincent and the Grenadines. Any therapeutic use would require formal research approvals. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Because ayahuasca preparations contain DMT (a controlled psychotropic compound), ayahuasca is similarly controlled and is not part of any authorised, reimbursed medical programme in Saint Vincent and the Grenadines; ceremonial or religious exemptions are not documented in national policy sources. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing cacti are regulated by the implementing national drug control framework; there is no reimbursed medical programme for mescaline‑based therapies in Saint Vincent and the Grenadines. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The 2C‑family of substituted phenethylamines (e.g., 2C‑B, 2C‑I) are controlled under international and domestic psychotropic drug controls and are not part of any reimbursed medical programme in Saint Vincent and the Grenadines. # #.